In early 2026, the pharmaceutical industry is navigating a complex web of new safety reporting requirements for biological and gene therapies. This has triggered a surge in pharmacovigilance outsourcing, as companies seek to leverage global expertise to monitor drug reactions across diverse populations in real-time. The transition into 2026 is marked by the Indian Central Drugs Standard Control...

The intersection of biotechnology and information technology is defining the current landscape of cellular research. We are moving away from manual observation toward automated, high-content imaging systems that can track cellular changes in real-time. This is particularly important in 3D cultures, where the depth and complexity of the tissue model make traditional microscopy difficult. Today,...

The gene editing landscape is moving away from the "one-size-fits-all" approach of the early CRISPR days toward highly specialized, niche applications. One of the most prominent trends is the development of "Inducible CRISPR," where the editing activity can be turned on or off using specific drugs or light. This provides a layer of control that is vital for therapies where the timing of the...